Patents by Inventor Lorraine SULLIVAN

Lorraine SULLIVAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified relaxin polypeptides and their uses
    Patent number: 11786578
    Abstract: Modified relaxin polypeptides and their uses thereof are provided. Exemplary embodiments provide relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol. Additionally, use of said relaxin polypeptides for treatment of disease, such as heart failure, is also provided.
    Type: Grant
    Filed: March 3, 2022
    Date of Patent: October 17, 2023
    Assignee: AMBRX, INC.
    Inventors: Vadim Kraynov, Nick Knudsen, Amha Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan
  • Modified Relaxin Polypeptides and Their Uses
    Publication number: 20230028168
    Abstract: Modified relaxin polypeptides and their uses thereof are provided
    Type: Application
    Filed: July 25, 2022
    Publication date: January 26, 2023
    Inventors: Vadim KRAYNOV, Nick Knudsen, Amha Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan
  • Nucleic acids encoding modified relaxin polypeptides
    Patent number: 11439710
    Abstract: Modified relaxin polypeptides and their uses thereof are provided.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: September 13, 2022
    Assignee: AMBRX, INC.
    Inventors: Vadim Kraynov, Nick Knudsen, Amha Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan
  • Modified Relaxin Polypeptides and Their Uses
    Publication number: 20220257720
    Abstract: Modified relaxin polypeptides and their uses thereof are provided. Exemplary embodiments provide relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol. Additionally, use of said relaxin polypeptides for treatment of disease, such as heart failure, is also provided.
    Type: Application
    Filed: March 3, 2022
    Publication date: August 18, 2022
    Inventors: Vadim KRAYNOV, Nick KNUDSEN, Amha HEWET, Kristine DE DIOS, Jason PINKSTAFF, Lorraine SULLIVAN
  • Methods of treating heart failure and fibrotic disorders using modified relaxin polypeptides
    Patent number: 11311605
    Abstract: Modified relaxin polypeptides and their uses thereof are provided. Exemplary embodiments provide relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol. Additionally, use of said relaxin polypeptides for treatment of disease, such as heart failure, is also provided.
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: April 26, 2022
    Assignee: AMBRX, INC.
    Inventors: Vadim Kraynov, Nick Knudsen, Amha Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan
  • Modified Relaxin Polypeptides and Their Uses
    Publication number: 20200360525
    Abstract: Modified relaxin polypeptides and their uses thereof are provided
    Type: Application
    Filed: May 28, 2020
    Publication date: November 19, 2020
    Inventors: Vadim KRAYNOV, Nick KNUDSEN, Amha HEWET, Kristine DE DIOS, Jason PINKSTAFF, Lorraine SULLIVAN
  • MODIFIED RELAXIN POLYPEPTIDES AND THEIR USES
    Publication number: 20200360485
    Abstract: Modified relaxin polypeptides and their uses thereof are provided. Exemplary embodiments provide relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol. Additionally, use of said relaxin polypeptides for treatment of disease, such as heart failure, is also provided.
    Type: Application
    Filed: May 27, 2020
    Publication date: November 19, 2020
    Inventors: Vadim KRAYNOV, Nick KNUDSEN, Amha HEWET, Kristine DE DIOS, Jason PINKSTAFF, Lorraine SULLIVAN
  • Methods of treatment using modified relaxin polypeptides comprising a non-naturally encoded amino acid
    Patent number: 10751391
    Abstract: Modified relaxin polypeptides and their uses thereof are provided. Exemplary embodiments provide relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol. Additionally, use of said relaxin polypeptides for treatment of disease, such as heart failure, is also provided.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: August 25, 2020
    Assignee: AMBRX, INC.
    Inventors: Vadim Kraynov, Nick Knudsen, Amha Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan
  • Modified relaxin polypeptides comprising a non-naturally encoded amino acid in the A chain
    Patent number: 10702588
    Abstract: Modified relaxin polypeptides and their uses thereof are provided.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: July 7, 2020
    Assignee: AMBRX, INC.
    Inventors: Vadim Kraynov, Nick Knudsen, Amha Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan
  • Therapeutic uses of modified relaxin polypeptides
    Patent number: 10253083
    Abstract: Therapeutic uses of modified relaxin polypeptides for the treatment of cardiovascular disease, treatment of heart failure, and decreasing fibrotic disorders are provided. Exemplary embodiments provide for the use of relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: April 9, 2019
    Assignee: AMBRX, INC.
    Inventors: Vadim Kraynov, Nick Knudsen, Amha Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan
  • Modified Relaxin Polypeptides and Their Uses
    Publication number: 20180311368
    Abstract: Modified relaxin polypeptides and their uses thereof are provided
    Type: Application
    Filed: March 30, 2018
    Publication date: November 1, 2018
    Inventors: Vadim KRAYNOV, Nick KNUDSEN, Amha HEWET, Kristine DE DIOS, Jason PINKSTAFF, Lorraine SULLIVAN
  • Method of treating heart failure with modified relaxin polypeptides
    Patent number: 9962450
    Abstract: Modified relaxin polypeptides and their uses thereof are provided.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: May 8, 2018
    Assignee: AMBRX, INC.
    Inventors: Vadim Kraynov, Nick Knudsen, Amha Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan
  • Modified leptin polypeptides and their uses
    Patent number: 9938333
    Abstract: Modified human leptin polypeptides and uses thereof are provided.
    Type: Grant
    Filed: February 5, 2009
    Date of Patent: April 10, 2018
    Assignee: Ambrx, Inc.
    Inventors: Vadim Kraynov, Anna-Maria A. Hays Putnam, Nick Knudsen, Jason Pinkstaff, Heather Myler, Lorraine Sullivan
  • THERAPEUTIC USES OF MODIFIED RELAXIN POLYPEPTIDES
    Publication number: 20170226178
    Abstract: Modified relaxin polypeptides and their uses thereof are provided. Exemplary embodiments provide relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol. Additionally, use of said relaxin polypeptides for treatment of disease, such as heart failure, is also provided.
    Type: Application
    Filed: December 21, 2016
    Publication date: August 10, 2017
    Inventors: VADIM KRAYNOV, NICK KNUDSEN, AMHA HEWET, KRISTINE DE DIOS, JASON PINKSTAFF, LORRAINE SULLIVAN
  • Therapeutic uses of modified relaxin polypeptides
    Patent number: 9567386
    Abstract: Modified relaxin polypeptides and their uses, including therapeutic uses thereof for the treatment of a fibrotic disorder or heart failure are provided. Exemplary embodiments provide for the use of relaxin polypeptides which include one or more amino acid substitutions with natural or non-naturally encoded amino acids, and/or linkage to a water-soluble polymer, such as polyethylene glycol.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: February 14, 2017
    Assignee: AMBRX, INC.
    Inventors: Vadim Kraynov, Nick Knudsen, Amha Hewet, Kristine de Dios, Jason Pinkstaff, Lorraine Sullivan
  • Modified Relaxin Polypeptides and Their Uses
    Publication number: 20170035897
    Abstract: Modified relaxin polypeptides and their uses thereof are provided
    Type: Application
    Filed: August 17, 2016
    Publication date: February 9, 2017
    Inventors: Vadim KRAYNOV, Nick KNUDSEN, Amha HEWET, Kristine DE DIOS, Jason PINKSTAFF, Lorraine SULLIVAN
  • Nucleic acids encoding modified relaxin polypeptides
    Patent number: 9452222
    Abstract: Modified relaxin polypeptides and their uses thereof are provided.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: September 27, 2016
    Assignee: AMBRX, INC.
    Inventors: Vadim Kraynov, Nick Knudsen, Ahma Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan
  • Modified Relaxin Polypeptides and Their Uses
    Publication number: 20140194357
    Abstract: Modified relaxin polypeptides and their uses thereof are provided
    Type: Application
    Filed: January 10, 2014
    Publication date: July 10, 2014
    Applicant: AMBRX, INC.
    Inventors: VADIM KRAYNOV, NICK KNUDSEN, AHMA HEWET, KRISTINE DE DIOS, JASON PINKSTAFF, LORRAINE SULLIVAN
  • Relaxin polypeptides comprising non-naturally encoded amino acids
    Patent number: 8735539
    Abstract: Modified relaxin polypeptides and their uses are provided. In one aspect, the disclosure provides a relaxin polypeptide comprising one or more non-naturally encoded amino acids. The polypeptide may be linked to a linker, polymer, or biologically active molecule. The serum half-life of the relaxin polypeptide may be enhanced relative to the unconjugated form. In another aspect, the disclosure provides methods of treating a patient having a disorder modulated by relaxin.
    Type: Grant
    Filed: August 17, 2011
    Date of Patent: May 27, 2014
    Assignee: Ambrx, Inc.
    Inventors: Vadim Kraynov, Nick Knudsen, Ahma Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan
  • Relaxin polypeptides comprising non-naturally encoded amino acids
    Patent number: 8691940
    Abstract: Modified relaxin polypeptides and their uses are provided. In one aspect, the disclosure provides a relaxin polypeptide comprising one or more non-naturally encoded amino acids. The polypeptide may be linked to a linker, polymer, or biologically active molecule. The serum half-life of the relaxin polypeptide may be enhanced relative to the unconjugated form. In another aspect, the disclosure provides methods of treating a patient having a disorder modulated by relaxin.
    Type: Grant
    Filed: August 17, 2011
    Date of Patent: April 8, 2014
    Assignee: Ambrx, Inc.
    Inventors: Vadim Kraynov, Nick Knudsen, Ahma Hewet, Kristine De Dios, Jason Pinkstaff, Lorraine Sullivan